Metastatic RCC
Metastatic RCC is a systemic disease stratified by risk group, treated primarily with immunotherapy/targeted agents, with surgery (cytoreduction, metastasectomy) reserved for selected patients.
The big picture
Metastatic RCC is managed by prognostic risk group (favourable / intermediate / poor, based on clinical and lab factors). Systemic therapy — immune checkpoint inhibitor combinations and targeted (anti-angiogenic) agents — is the backbone; surgery is selective.
Risk-stratify, lead with systemic therapy, and reserve cytoreductive surgery/metastasectomy for selected patients who will benefit.
Mechanism pathway
Tap any step to see why it happens.
Interactive — metastatic ccRCC first-line therapy (IMDC)
Diagnostic algorithm
Each step answers one question. Tap to expand.
Treatment ladder
Systemic therapy chosen by risk group, with selective surgery and integrated palliative care.
Procedure chooser
- Cytoreductive nephrectomy in selected good-performance patients
- Metastasectomy for limited/resectable disease
Follow-up
- Treatment response and toxicity
- Symptom burden
- New metastatic sites
- Per systemic-therapy protocol
- Response/stability with good quality of life
- Progression or intolerable toxicity
- Response assessment; new symptoms
- Treatment toxicity; progression; end-of-life planning
If treatment fails
On progression, ask: is this true progression on this line, a single progressing site amenable to local therapy, or toxicity limiting therapy?
Memory hooks
Metastatic RCC = systemic, but treatable.
Risk group drives therapy.
IO combinations / targeted agents are the backbone.
Cytoreduction/metastasectomy = selected patients.
Board traps
Assuming every metastatic patient needs upfront nephrectomy.
Ignoring brain metastases needing local therapy.
Mislabelling an immune-related adverse event as disease progression.
Clinical cases
A patient with newly diagnosed metastatic clear-cell RCC has good performance status and intermediate-risk features.
What is the backbone of initial management?